Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2026-02-25 @ 5:21 AM
Study NCT ID:
NCT01784120
Status:
UNKNOWN
Last Update Posted:
2016-02-10
First Post:
2013-01-30
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
Sponsor:
Gachon University Gil Medical Center
Organization:
Study Overview
Official Title:
A Phase II Trial of Doxorubicin and Genexol-PM in Patients With Advanced Breast Cancer
Status:
UNKNOWN
Status Verified Date:
2016-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate efficacy and toxicity of doxorubicin/Genexol-PM in metastatic breast cancer
1. Primary Purpose: response rate
2. Secondary purpose: toxicity, progression-free survival, overall survival
1. Primary Purpose: response rate
2. Secondary purpose: toxicity, progression-free survival, overall survival
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: